Announcements
- CytoDyn Announces FDA Has Lifted Clinical Hold
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
- CytoDyn Announces Webcast to Provide Company Update
- CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
- November 2023 Letter to Shareholders
- CytoDyn Announces Company Updates and Investment Community Update Webcast
More ▼
Key statistics
On Wednesday, Cytodyn Inc (296:BER) closed at 0.00, -100.00% above its 52-week low of 0.12, set on Nov 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 0.18 |
Offer | 0.270 |
Previous close | 0.00 |
Average volume | -- |
---|---|
Shares outstanding | 993.37m |
Free float | 985.39m |
P/E (TTM) | -- |
Market cap | 149.00m USD |
EPS (TTM) | -0.055 USD |
Data delayed at least 15 minutes, as of Dec 20 2023 08:52 GMT.
More ▼